TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Concord Biotech Ltd.

CONCORDBIO on NSE · 19 Nov 2026

NIFTY 500

556.40 ▼ -0.82 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Guidance tracker

What CONCORDBIO guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
03 Nov 2026Concord Biotech Limited filed the transcript of its Q2 & H1 FY27 earnings call held on October 28, 2026, under Regulation 30(6) of the SEBI LODR Regulations, 2015. Management said Q2 FY27 revenue rose 25% year-on-year to Rs. 309.1 crore and H1 FY27 revenue rose 26% to Rs. 566.6 crore; Q2 FY27 gross margin was... NSE copy No results filed since
07 Aug 2026Concord Biotech filed the transcript of its Q1 FY27 earnings call held on August 3, 2026, under Regulation 30(6) of the SEBI LODR Regulations, 2015. Management said Q1 FY27 revenue was INR257 crores, up 26% year-on-year from INR204 crores; API revenue was INR219 crores (up 42%) and formulation revenue was INR39... NSE copy +11.1 %+25.1 %-7.8 %
01 Aug 2026Concord Biotech filed the investor presentation on its unaudited standalone and consolidated results for the first quarter ended June 30, 2026 (Q1FY27). Consolidated revenue rose 26% year-on-year to Rs. 257.5 crore (Q1FY26: Rs. 204.0 crore); PAT rose 31% to Rs. 57.7 crore (Rs. 44.1 crore); EBITDA rose 34% to Rs.... NSE copy +11.1 %+25.1 %-7.8 %
05 Jun 2026Concord Biotech filed the transcript of its Q4 and FY26 earnings conference call held on June 1, 2026, under Regulation 30(6) of the SEBI LODR Regulations. Management (CEO Ankur Vaid) said FY26 was challenging, citing slower US procurement in H1, CDSCO approval issues that restricted European supplies for about 3... NSE copy +32.8 %+26.2 %-0.4 %
30 May 2026Concord Biotech filed its investor presentation on audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Consolidated revenue was Rs. 326.1 crore in Q4FY26 (Rs. 429.9 crore in Q4FY25) and Rs. 1,054.9 crore in FY26 (Rs. 1,200.1 crore in FY25). Consolidated PAT... NSE copy +32.8 %+26.2 %-0.4 %
18 Feb 2026Concord Biotech filed the transcript of its Q3 and nine months FY26 earnings call held on February 12, 2026, under Regulation 30(6) of the SEBI LODR Regulations. Management said Q3 FY26 revenue was INR 278 crores (up 14% year-on-year) and nine-month FY26 revenue was INR 729 crores (down 5% from INR 770 crores); Q3... NSE copy -36.8 %-24.1 %+1.0 %
19 Nov 2025Concord Biotech filed the transcript of its Q2 and H1 FY26 earnings conference call held on November 14, 2025, under Regulation 30(6) of the SEBI LODR; the transcript and audio are on the company website. Management said Q2 FY26 revenue was Rs. 247 crores (down about 20% year-on-year, up 21% quarter-on-quarter) and... NSE copy -15.1 %+13.7 %-1.3 %
10 Aug 2025Concord Biotech Limited filed its investor presentation on financial results for the first quarter ended June 30, 2025 (Q1FY26). Consolidated revenue was Rs. 204.0 crore in Q1FY26 versus Rs. 215.8 crore in Q1FY25, down 5%, which management attributed to lumpiness in customer procurement patterns. Consolidated... NSE copy -33.6 %-20.4 %+2.8 %
06 Jun 2025Concord Biotech filed the transcript of its Q4 and FY25 earnings conference call held on May 30, 2025, with the audio recording also uploaded to its website. Management said Q4 FY25 revenue grew 35% to INR 430 crores and FY25 revenue was INR 1,200 crores (up 18%); Q4 PAT was INR 140 crores (up 48%) and FY25 PAT was... NSE copy -26.1 %-5.5 %+0.4 %
21 Feb 2025Concord Biotech filed transcript of its Q3 FY25 and nine months FY25 earnings conference call held on February 14, 2025, under Regulation 30(6) of SEBI LODR; transcript and audio are on the company website. Management said Q3 FY25 revenue from operations was INR 244 crores vs INR 240 crores in Q3 FY24 (1% growth);... NSE copy +47.8 %+34.8 %+4.9 %
14 Feb 2025Investor presentation for the third quarter and nine months ended December 31, 2024, filed under Regulation 30 of the SEBI LODR Regulations. Q3FY25 consolidated revenue was Rs. 244.2 crs (up 1% YoY from Rs. 240.8 crs); 9MFY25 revenue was Rs. 770.2 crs (up 10% from Rs. 698.0 crs). Q3FY25 EBITDA was Rs. 98.0 crs... NSE copy +47.8 %+34.8 %+4.9 %
19 Nov 2024Concord Biotech filed the transcript of its Q2 and H1 FY25 earnings conference call held on November 12, 2024, per Regulation 30(6) of the SEBI LODR. Management reported Q2 FY25 revenue of INR 310 crores (vs INR 262 crores in Q2 FY24) and PAT of INR 99 crores (vs INR 84 crores), both up 18% year-on-year. Management... NSE copy -2.1 %+1.4 %-19.9 %

Filings tagged as guidance, newest first (12 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
27 Oct 2026Legal or regulatoryConcord Biotech filed an investor presentation on its unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter and half year ended September 30, 2026). Consolidated revenue for Q2FY27 was Rs. 309.1 crore, up 25% from Rs. 247.1 crore in Q2FY26; H1FY27 revenue was Rs. 566.6 crore, up 26% from Rs.... NSE copy
27 Oct 2026Management changeBoard meeting held October 27, 2026 approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports from statutory auditors BSR & Co. LLP. Board fixed Wednesday, November 04, 2026 as record date for identifying shareholders... NSE copy
30 May 2026Legal or regulatoryConcord Biotech filed its investor presentation on audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. Consolidated revenue was Rs. 326.1 crore in Q4FY26 (Rs. 429.9 crore in Q4FY25) and Rs. 1,054.9 crore in FY26 (Rs. 1,200.1 crore in FY25). Consolidated PAT... NSE copy
30 May 2026Management changeConcord Biotech's board, at its meeting on May 29, 2026, approved audited standalone and consolidated results for the fourth quarter and financial year ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP. The board recommended a dividend of Rs. 7.55 per equity share (face... NSE copy
29 May 2026Management changeConcord Biotech's board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP. The board recommended a dividend of Rs. 7.55 per equity share (face value Re. 1) for FY 2025-26, subject to shareholder approval at... NSE copy
29 May 2026Management changeConcord Biotech Limited filed the outcome of its board meeting held on May 29, 2026, approving audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP. The board recommended a dividend of Rs. 7.55 per equity... NSE copy
18 Feb 2026Legal or regulatoryConcord Biotech filed the transcript of its Q3 and nine months FY26 earnings call held on February 12, 2026, under Regulation 30(6) of the SEBI LODR Regulations. Management said Q3 FY26 revenue was INR 278 crores (up 14% year-on-year) and nine-month FY26 revenue was INR 729 crores (down 5% from INR 770 crores); Q3... NSE copy
11 Feb 2026Management changeInvestor presentation on unaudited standalone and consolidated results for Q3 and nine months ended December 31, 2025 (Q3FY26 and 9MFY26). Consolidated revenue was Rs. 277.8 crore in Q3FY26 vs Rs. 244.2 crore in Q3FY25; nine-month revenue was Rs. 728.8 crore vs Rs. 770.2 crore. Consolidated PAT was Rs. 63.7 crore... NSE copy
11 Feb 2026Management changeBoard of Concord Biotech Limited approved unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, with Limited Review Reports (unmodified opinion) from statutory auditors BSR & Co. LLP. The Board appointed Mr. Paritosh Trivedi as Company Secretary,... NSE copy
18 Dec 2025Management changeConcord Biotech Limited filed the outcome of its board meeting held on December 18, 2025 (meeting ran from 12:10 PM to 12:50 PM). The board, on recommendation of the Nomination and Remuneration Committee and Audit Committee, approved the appointment of Mr. Raviraj Karia as Chief Financial Officer and Key Managerial... NSE copy
19 Nov 2025Legal or regulatoryConcord Biotech filed the transcript of its Q2 and H1 FY26 earnings conference call held on November 14, 2025, under Regulation 30(6) of the SEBI LODR; the transcript and audio are on the company website. Management said Q2 FY26 revenue was Rs. 247 crores (down about 20% year-on-year, up 21% quarter-on-quarter) and... NSE copy
13 Nov 2025Legal or regulatoryInvestor presentation filed for Q2 and H1 FY26 results (quarter and half year ended September 30, 2025). Consolidated revenue for Q2FY26 was Rs. 526.0 crore versus Rs. 310.2 crore in Q2FY25; H1FY26 revenue was Rs. 451.1 crore versus Rs. 247.1 crore in H1FY25 (as printed in the slides). Consolidated EBITDA for... NSE copy
13 Nov 2025Legal or regulatoryConcord Biotech Limited's board on November 13, 2025 approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025; Q2 standalone revenue from operations was Rs. 24,705.75 lakhs and standalone profit after tax was Rs. 6,289.63 lakhs (vs Rs. 9,869.94 lakhs in Q2 FY25).... NSE copy
18 Aug 2025Legal or regulatoryConcord Biotech filed the transcript of its Q1 FY26 earnings conference call held on August 11, 2025, under Regulation 30(6) of the SEBI LODR, and uploaded it to its website. Management reported Q1 FY26 revenue of INR 204 crores, down 5% from INR 216 crores a year earlier; API revenue of INR 153.8 crores (down 10%)... NSE copy
06 Jun 2025Legal or regulatoryConcord Biotech filed the transcript of its Q4 and FY25 earnings conference call held on May 30, 2025, with the audio recording also uploaded to its website. Management said Q4 FY25 revenue grew 35% to INR 430 crores and FY25 revenue was INR 1,200 crores (up 18%); Q4 PAT was INR 140 crores (up 48%) and FY25 PAT was... NSE copy
29 May 2025Legal or regulatory, Management changeBoard of Concord Biotech Limited approved and took on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with unmodified audit opinion from BSR & Co. LLP. The Board recommended a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY... NSE copy
29 May 2025Management changeBoard of Concord Biotech Limited approved and took on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with unmodified audit opinion from BSR & Co. LLP. The Board recommended a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY... NSE copy
29 May 2025Legal or regulatory, Management changeConcord Biotech Limited's board approved and took on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, on May 29, 2025; statutory auditors BSR & Co. LLP issued unmodified audit opinions. The board recommended a dividend of Rs. 10.70 per equity... NSE copy
29 May 2025Legal or regulatory, Management changeConcord Biotech Limited filed the outcome of its board meeting held on May 29, 2025, approving audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with unmodified audit opinions from BSR & Co. LLP. The board recommended a dividend of Rs. 10.70 per equity... NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (19 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in